MHRA and NICE Launch Evidence Call on Digital Mental Health Programme

The survey will assess how Phase 1 resources have been received and used, and runs until 26 February 2027.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) have launched a call for evidence to evaluate resources created under the Wellcome-funded Digital Mental Health Technologies (DMHT) programme. The survey opened on 5 November 2026 and will close on 26 February 2027.

The organisations are seeking feedback from developers and manufacturers of digital mental health technologies, healthcare professionals, researchers, policymakers, regulators, people with lived experience of mental health conditions, carers and members of the public.

According to the MHRA and NICE, the survey is part of the programme’s Phase 1 evaluation. It aims to assess how the resources have been received and used across the sector, and whether they have influenced users’ knowledge, confidence, decision-making and professional practice.

The resources were designed to support the safe development, regulation, evaluation and adoption of digital mental health technologies, including mental health apps and other digital tools. Findings will help determine whether Phase 1 outputs met their intended objectives and will inform the future direction of Phase 2.

The organisations say stakeholders are encouraged to take part whether they have engaged extensively, minimally or not at all with the existing resources. The feedback is intended to identify strengths, highlight areas for improvement and shape future work on the safety and effectiveness of digital mental health technologies.

PN

Priya Nair

Priya Nair is a health product quality and procurement analyst covering first aid kits, wound dressings, and absorbent hygiene products. Her method compares supplier evidence, packaging integrity, absorbency and peel-force metrics, batch traceability, and applicable standards such as ISO 11948-1 without treating a standard as proof of a specific product outcome. She supports private label managers, quality assurance teams, and procurement officers in sample acceptance, labeling review, shelf-life planning, and recall readiness while excluding patient care and clinical decisions.